viewCreso Pharma Ltd

Creso Pharma appoints Canopy Growth Corp founder and ex-CEO Bruce Linton as strategic advisor

“We anticipate that his appointment will greatly assist us in achieving our near-term operational milestones and longer-term goals,” says CEO Miri Halperin Wernli.

Creso Pharma Ltd - Creso Pharma appoints Canopy Growth Corporation founder and ex-CEO Bruce Linton as strategic advisor
Bruce Linton is one of the world’s leading cannabis executives and an accomplished entrepreneur.

Creso Pharma Ltd (ASX:CPH) (OTCMKTS:COPHF) (FRA:1X8) has appointed NYSE-listed Canopy Growth Corp (NYSE:CGC) founder and former chief executive officer Bruce Linton as strategic advisor.

Linton is one of the world’s leading cannabis executives and an accomplished entrepreneur, with extensive sector experience as a founder, CEO, board member and adviser to a number of global cannabis companies.

He founded Canopy Growth and turned it into the first cannabis producing company listed on the New York Stock Exchange, with a peak market capitalisation of US$15 billion during his six-year tenure.

Deep network of industry contacts

CPH chief executive officer Miri Halperin Wernli said: “Bruce brings a wealth of invaluable knowledge and a deep network of cannabis industry contacts to Creso Pharma and we anticipate that his appointment will greatly assist us in achieving our near term operational milestones and longer-term goals.

“We continue to target international distribution agreements in a number of new markets and progress product development initiatives that will unlock considerable shareholder value. We look forward to providing further updates in the near-term.”

Shape strategy

As strategic advisor, Linton will leverage his connections, expertise and influence in the industry to consult and work closely with Creso Pharma’s board to shape the company’s long-term strategy and various near-term corporate and operational initiatives.

Linton believes Creso Pharma is in an optimal position to excel internationally and continue to develop innovative products to complement its existing portfolio.

He says he was attracted to Creso Pharma by its unique IP, established global distribution footprint and robust product pipeline targeting distinct categories.

First cannabis producing company on NYSE

The new strategic advisor has extensive experience in the sector.

At Canopy Growth, he secured 16 rounds of financing of more than US$5 billion in public capital markets and private placements and was involved in more than 30 merger and acquisitions.

After leaving Canopy Growth in 2019, Linton led direct investments into the sector and has held both management positions and strategic advisory roles.

He is the executive chair of Gage Cannabis Co and the co-chairman of technology company Martello Technologies Group Inc (CVE:MTLO).

Linton is also the co-founder of Ruckify Software.

He has also worked extensively with international institutions such as the World Bank and has diversified into the psychedelic drug space as director of psychedelic-inspired medicine company Mind Medicine Inc.

Quick facts: Creso Pharma Ltd

Price: 0.23 AUD

Market: ASX
Market Cap: $209.83 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Creso Pharma Ltd named herein, including the promotion by the Company of Creso Pharma Ltd in any Content on the Site, the Company receives from...


Creso Pharma subsidiary Mernova granted sales license from Health Canada

Creso Pharma (ASX:CPH) subsidiary Mernova managing director Jack Yu and vice president Isaac Allen joined Steve Darling from Proactive to discuss the granting of their sales license from Health Canada and what it allows them to do. Isaac Allen tells Proactive they are gearing up sales...

on 12/6/20

2 min read